TICE BCG Drug Profile

Summary for Tradename: TICE BCG

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for TICE BCG

See drug prices for TICE BCG

Pharmacology for TICE BCG

Physiological Effect	Actively Acquired Immunity Increased Immunologically Active Molecule Activity Increased Macrophage Proliferation
Established Pharmacologic Class	Live Attenuated Bacillus Calmette-Guerin Immunotherapy Live Attenuated Bacillus Calmette-Guerin Vaccine
Chemical Structure	BCG Vaccine Vaccines, Attenuated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for TICE BCG Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for TICE BCG Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for TICE BCG Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821		2036-03-30	Patent claims search
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821		2036-12-09	Patent claims search
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821		2037-01-25	Patent claims search

Market Dynamics and Financial Trajectory for TICE BCG

Last updated: February 19, 2026

What is TICE BCG and its clinical indication?

TICE BCG (Bacillus Calmette-Guérin) is a live attenuated vaccine derived from Mycobacterium bovis. It is approved for intravesical therapy in non-muscle invasive bladder cancer (NMIBC), particularly carcinoma in situ (CIS) and high-grade tumors. Its use involves instillation into the bladder to reduce recurrence and progression.

What is the current market landscape for TICE BCG?

The TICE BCG market is driven by bladder cancer treatment needs, regulatory approvals, and competition. The key market components include:

• Global sales: Estimated at approximately $900 million annually (as of 2022).
• Leading manufacturers: Merck & Co. (covering TICE BCG licensing), Sanofi, and other regional players.
• Market segmentation: U.S. accounts for roughly 60% of sales; Europe and Asia-Pacific hold the remaining share.

How is the market evolving?

Market growth drivers

1. High prevalence of bladder cancer: Approximately 81,000 cases in the U.S. annually (SEER, 2020).
2. Treatment adherence: TICE BCG is the standard of care for high-risk NMIBC; about 70% of eligible patients receive initial therapy.
3. Limitations of alternatives: Limited effective chemotherapies and increasing resistance boost TICE BCG’s usage.
4. Regulatory status: The U.S. FDA approved TICE BCG in 1990; no significant regulatory hurdles recently.

Market challenges

1. Manufacturing constraints: BCG production complexity creates supply shortages.
2. Emerging therapies: Novel immunotherapies and intravesical agents are in development, threatening market share.
3. Pricing pressures: Payor restrictions and cost-containment measures impact revenue.

Patent and licensing issues

• No active patents on TICE BCG. Company licensing deals (e.g., Merck's licensing) impact pricing and supply.
• Recent efforts to develop BCG strain alternatives could alter market dynamics, though none have achieved broad approval yet.

What is the financial trajectory?

Revenue projections

• Current revenue estimate: $900 million globally (2022).
• Growth rate: Compound annual growth rate (CAGR) projected at 3% to 5% over the next five years, driven by bladder cancer prevalence and treatment adherence.
• Impact of supply constraints: Short-term revenue stagnation or decline possible if manufacturing issues persist.

Cost considerations

• Manufacturing costs: High, due to live bacterial culture complexity, influencing pricing strategies.
• Pricing: Approximate cost per course ranges from $20,000 to $30,000 depending on region and healthcare provider contracts.
• Market share shifts: If newer therapies gain approval, TICE BCG’s market share could decrease, affecting revenue.

Competitive landscape impact

• New immunotherapies such as checkpoint inhibitors (e.g., pembrolizumab) are in late-stage development, possibly affecting TICE BCG revenues after regulatory approval.
• Biosimilar or alternative BCG strains could further pressure pricing and market share.

Future revenue scenarios

Scenario	Assumption	Impact
Optimistic	Manufacturing stabilizes; no regulatory hurdles	Revenue growth at 5% CAGR
Conservative	Supply issues persist; competition intensifies	Flat or declining revenue
Pessimistic	Market shifts significantly toward new therapies	Revenue declines by 10-15% annually

What factors influence the financial outlook?

• Supply chain stability: Addressing manufacturing bottlenecks is critical.
• Regulatory trends: Approval of alternative BCG strains or competitors impacts market share.
• Clinical guidelines: Adoption of new standard-of-care protocols influences usage rates.
• Pricing and reimbursement policies: Particularly in the U.S. and Europe.

Key takeaways

• TICE BCG remains the standard therapy for high-risk NMIBC, with steady global sales.
• Market growth is moderate, constrained by supply issues and emerging competitors.
• Revenue projections depend heavily on manufacturing stability and regulatory developments.
• Potential for market erosion exists with the advent of novel immunotherapies and biosimilars.
• Strategic responses should focus on securing supply chains, engaging with regulators, and monitoring innovative therapies.

FAQs

1. What are the main competitors to TICE BCG?
Non-licensed BCG strains, biosimilars, and emerging intravesical immunotherapies are competitors.

2. How does supply chain instability affect TICE BCG?
Manufacturing complexity often causes shortages, suppressing revenue and limiting patient access.

3. Are there regulatory hurdles for new BCG formulations?
Regulatory approval requires demonstration of safety and efficacy; no major hurdles currently exist for licensed TICE BCG, but new formulations face rigorous review.

4. How might alternative therapies impact market share?
If clinical trials show superior efficacy or safety, new therapies could displace TICE BCG, reducing its revenue.

5. What strategies can mitigate revenue risks?
Enhancing manufacturing capacity, securing long-term licensing agreements, and investing in research for next-generation therapies.

---

References

[1] Surveillance, Epidemiology, and End Results Program. (2020). Bladder Cancer Statistics. National Cancer Institute.
[2] FDA. (1990). TICE Bacillus Calmette-Guérin (BCG) Monograph. U.S. Food and Drug Administration.
[3] MarketWatch. (2022). BCG Vaccine Market Size and Forecast.
[4] BioCentury. (2021). Market traction and developments in bladder cancer therapies.
[5] Pharmaceutical Technology. (2022). Biological manufacturing challenges.